Slide Source:www.lipidsonline.org

Lipid and Lipoprotein Parameters at Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: Baseline and Drug Treatment: METEOR METEOR TrialTrial

Baseline, Mean (SD)Time-Weighted Average

During Treatment, Mean (SD)*

Rosuvastatin(n=624)

Placebo(n=252)

Rosuvastatin(n=624)

Placebo(252)

Lipid levels, mg/dL LDL Cholesterol 155 (24.1) 154 (24.2) 78 (27.5) 152 (23.4)

Total Cholesterol 229 (28.7) 230 (27.7) 151 (31.0) 230 (27.7)

HDL Cholesterol 50 (9.0) 49 (9.2) 53 (9.6) 50 (9.4)

Triglycerides 126 (64.3) 134 (67.8) 98 (47.7) 139 (69.6)

Non-HDL Cholesterol 180 (27.4) 181 (27.2) 98 (30.9) 180 (26.8)

Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.SI conversion factors: To convert HDL, LDL, and total cholesterol to mmol/L, multiply by 0.0259; triglycerides to mmol/L, multiply by 0.0113.*Time-weighted average was defined as the lipid value multiplied by number of days since the last lipid assessment, summed for all lipid observations and divided by the sum of days between all visits. Results are least-squares means from analysis of covariance.

Crouse JR et al. JAMA 2007;297:1344-1353

Slide Source:www.lipidsonline.org

Lipid and Lipoprotein Parameters at Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: Baseline and Drug Treatment: METEOR METEOR TrialTrial

% Change (SE)†

Rosuvastatin(n=624)

Placebo(n=252)

Lipid levels, mg/dL LDL Cholesterol −48 (0.7) −0.3 (1.1)

Total Cholesterol −33.7 (0.5) 0.3 (0.8)

HDL Cholesterol 8.0 (0.6) 2.8 (0.9)

Triglycerides −15.7 (1.4) 10.1 (2.3)

Non-HDL Cholesterol −45.1 (0.6) 0 (0.98)

Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.SI conversion factors: To convert HDL, LDL, and total cholesterol to mmol/L, multiply by 0.0259; triglycerides to mmol/L, multiply by 0.0113.†P<.001 for all comparisons of rosuvastatin with placebo.

Crouse JR et al. JAMA 2007;297:1344-1353

Slide Source:www.lipidsonline.org

Changes in the Primary and Changes in the Primary and Secondary End Points: Secondary End Points: METEOR TrialMETEOR Trial

Change in CIMT (95% CI), mm/y p value

Rosuvastatin (n = 624)

Placebo (n = 252) Difference

Rosuvastatinvs Placebo

Within Rosuvastatin

Group vs No Change

Primary Maximum CIMT for 12 carotid artery sites

−0.0014(−0.0041 to

0.0014)

0.0131(0.0087 to

0.0174)

−0.0145(−0.0196 to −0.0093) <.001 .32

Secondary Maximum CIMT (4 sites each) Common carotid artery sites

−0.0038(−0.0064 to

−0.0013)

0.0084(0.0043 to

0.0124)

−0.0122(−0.0170 to

−0.0074) <.001 .004

Carotid bulb sites

−0.0040(−0.0090 to

0.0010)

0.0172(0.0094 to

0.0251)

−0.0212(−0.0306 to

−0.0119) <.001 .11

Internal carotid artery sites

0.0039(−0.0009 to

0.0088)

0.0145(0.0068 to

0.0221)

−0.0105(−0.0196 to

−0.0015) .02 .11

Mean CIMT (4 sites) Common carotid artery sites

0.0004(−0.0011 to

0.0019)

0.0088(0.0064 to

0.0112)

−0.0085(−0.0113 to

−0.0056) <.001 .64

Crouse JR et al. JAMA 2007;297:1344-1353

Abbreviations: CI, confidence interval; CIMT, carotid intima-media thickness

Slide Source:www.lipidsonline.org

Change in Maximum Carotid Intima-Media Change in Maximum Carotid Intima-Media Thickness (CIMT) for the Primary End Point: Thickness (CIMT) for the Primary End Point: METEOR TrialMETEOR Trial

Crouse JR et al. JAMA 2007;297:1344-1353

Change in M

axim

um

CIM

T,

mm Placebo

Rosuvastatin

0 6 12 2418

Time, mo

-0.04

-0.03

-0.02

-0.01

0.00

0.01

0.02

0.03

0.04